Literature DB >> 14688096

Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Margret Y Richter1, Håvard Jakobsen, Alda Birgisdottir, Jean-François Haeuw, Ultan F Power, Giuseppe Del Giudice, Antonella Bartoloni, Ingileif Jonsdottir.   

Abstract

The immune system of the newborn is immature, and therefore it is difficult to induce protective immunity by vaccination in the neonatal period. Immunization of mothers during pregnancy against infections caused by encapsulated bacteria could thus be particularly attractive, as infants do not respond to polysaccharide (PS) antigens. Transmission of maternal vaccine-specific antibodies and protection of offspring against pneumococcal bacteremia and/or lung infection were studied in a neonatal murine model of pneumococcal immunization and infections. Adult female mice were immunized with native pneumococcal PS (PPS) of serotypes 1, 6B, and 19F or PPS conjugated to tetanus protein (Pnc-TT), and PPS-specific antibodies were measured in sera of mothers and their offspring. Effective transmission of maternal antibodies was observed, as PPS-specific immunoglobulin G levels in 3-week-old offspring of immunized mothers were 37 to 322% of maternal titers, and a significant correlation between maternal and offspring antibody levels was observed. The PPS-specific antibodies persisted for several weeks but slowly decreased over time. Offspring of Pnc-TT-immunized mothers were protected against pneumococcal infections with homologous serotypes, whereas PPS immunization of mothers did not protect their offspring, in agreement with the low titer of maternal PPS specific antibodies. When adult female mice were immunized with a meningococcal serogroup C conjugate vaccine (MenC-CRM), antibody response and transmission were similar to those observed for pneumococcal antibodies. Importantly, bactericidal activity was demonstrated in offspring of MenC-CRM-immunized mothers. These results demonstrate that this murine model of pneumococcal immunization and infections is suitable to study maternal immunization strategies for protection of offspring against encapsulated bacteria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14688096      PMCID: PMC343960          DOI: 10.1128/IAI.72.1.187-195.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants.

Authors:  H Sarvas; S Kurikka; I J Seppälä; P H Mäkelä; O Mäkelä
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

2.  Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate.

Authors:  L C Paoletti; J Pinel; R C Kennedy; D L Kasper
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

3.  Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat.

Authors:  D M Roberts; M Guenthert; R Rodewald
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

4.  Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  L C Paoletti; M R Wessels; A K Rodewald; A A Shroff; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

5.  Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Authors:  P Costantino; S Viti; A Podda; M A Velmonte; L Nencioni; R Rappuoli
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

6.  Mouse MHC class I-like Fc receptor encoded outside the MHC.

Authors:  J J Ahouse; C L Hagerman; P Mittal; D J Gilbert; N G Copeland; N A Jenkins; N E Simister
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422

7.  Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.

Authors:  J C Butler; R F Breiman; J F Campbell; H B Lipman; C V Broome; R R Facklam
Journal:  JAMA       Date:  1993-10-20       Impact factor: 56.272

8.  Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.

Authors:  L C Madoff; L C Paoletti; J Y Tai; D L Kasper
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

9.  Decline of Haemophilus influenzae type b disease in a region of high risk: impact of passive and active immunization.

Authors:  R J Singleton; N M Davidson; I J Desmet; J E Berner; R B Wainwright; L R Bulkow; C M Lilly; G R Siber
Journal:  Pediatr Infect Dis J       Date:  1994-05       Impact factor: 2.129

10.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; D Schulz; M Pizza; R Rappuoli; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

View more
  4 in total

1.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 2.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

3.  Streptococcus pneumoniae Transmission Is Blocked by Type-Specific Immunity in an Infant Mouse Model.

Authors:  Tonia Zangari; Yang Wang; Jeffrey N Weiser
Journal:  mBio       Date:  2017-03-14       Impact factor: 7.867

4.  Is Antibody-Dependent Enhancement of Trypanosoma cruzi Infection Contributing to Congenital/Neonatal Chagas Disease?

Authors:  Yves Carlier; Carine Truyens; Eric Muraille
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.